Disorders of iron metabolism. Part II: Iron deficiency and iron overload

Journal of Clinical Pathology

Volumn 64, Issue 4, 2011, Pages 287-296

  Muñoz, Manuel ^a   García Erce, José Antonio ^b   Remacha, Ángel Francisco ^c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ANTACID AGENT; ASCORBIC ACID; BICARBONATE; CHLORAMPHENICOL; COLESTYRAMINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; DOXYCYCLINE; ETIDRONIC ACID; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS ASPARTATE; FERROUS GLUCONATE; FERUMOXYTOL; IBANDRONIC ACID; IRON; IRON DEXTRAN; IRON SALT; LEVODOPA; LEVOTHYROXINE; MAGNESIUM SALT; MONOFER; PENICILLAMINE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TANNIN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANAPHYLAXIS; ANEMIA OF CHRONIC DISEASE; ARTHRALGIA; BLEEDING; BONE MARROW; CELL DAMAGE; CHRONIC DISEASE; CHRONIC FATIGUE SYNDROME; CHRONIC INFLAMMATION; CONGENITAL DYSERYTHROPOIETIC ANEMIA; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIARRHEA; DIET RESTRICTION; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DYSPNEA; ENTERITIS; ERYTHROCYTE; ERYTHROPOIESIS; EYE TOXICITY; FERRITIN BLOOD LEVEL; FLATULENCE; FOOT EDEMA; FUNCTIONAL IRON DEFICIENCY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC SCREENING; GROWTH DISORDER; HAND EDEMA; HEARING DISORDER; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INDIGESTION; INFECTION RATE; INFECTION RISK; IRON ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON DEPLETION; IRON INTAKE; IRON KINETICS; IRON OVERLOAD; IRON RESTRICTION; IRON STORAGE; IRON THERAPY; IRON TRANSPORT; LABORATORY TEST; LIVER BIOPSY; LIVER DYSFUNCTION; LUNG EDEMA; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; META ANALYSIS (TOPIC); MICROCYTIC ANEMIA; MOLECULAR DIAGNOSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENCHYMA; PATIENT COMPLIANCE; PATIENT MONITORING; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RELAPSE; RETICULOCYTE HEMOGLOBIN CONTENT; RETICULOCYTOSIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SINGLE DRUG DOSE; SKELETON MALFORMATION; STOMACH DISEASE; TACHYCARDIA; THALASSEMIA; THALASSEMIA MAJOR; THORAX PAIN; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; ZINC DEFICIENCY;

ALGORITHMS; ANEMIA, IRON-DEFICIENCY; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD;

EID: 79953122840     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.086991     Document Type: Review

References (60)

1. Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homeostasis. J Clin Pathol 2010. doi:10.1136/jcp.2010.079046.
2. Hersko C. Prevalence and causes of iron deficiency anaemia. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, eds. Disorders of Iron Homeostasis, Erythrocytes, Erythropoiesis. Paris: European School of Haematology, 2006:409-19.
3. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005;18:319-32. (Pubitemid 40298373)
4. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
5. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747-50.
6. Goognough LT. The relevance of iron in erythropoietin-stimulated erythropoiesis. Semin Hematol 2006;43(Suppl 6):S3-S8.
7. Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol 2009;15:4617-26.
8. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002:48:1066-76. (Pubitemid 34680903)
9. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-86.
10. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-7. (Pubitemid 27121300)
11. Beguin Y, Clemons GK, Pootrakul P, et al. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferring receptors and erythropoietin. Blood 1993;81:1067-76. (Pubitemid 23054847)
12. Thomas L, Franck S, Messinger M, et al. Reticulocyte hemoglobin measurementecomparison of two methods in the diagnosis of iron-restricted erythropoiesis. Clin Chem Lab Med 2005;43:1193-202. (Pubitemid 41600670)
13. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (RetHe) and assessment of iron-deficient states. Clin Lab Haematol 2006;28:303-8. (Pubitemid 44453675)
14. Canals C, Remacha AF, Sarda MP, et al. Clinical utility of the new Sysmex XE 2100 parameter - reticulocyte hemoglobin equivalent - in the diagnosis of anemia. Haematologica 2005;90:1133-4. (Pubitemid 41323514)
15. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008;103:1299-307. (Pubitemid 351678000)
16. Crichton RR, Danielsson BG, Geisser P. Iron Therapy with Special Emphasis on Intravenous Administration, Bremen: UNI-Med Verlag AG, 2008.
17. Maniatis A. The role of iron in anaemia management: can intravenous iron contribute to blood conservation? ISBT Science Series 2008;3:139-43.
18. Beris P, Muñoz M, García-Erce JA, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008;100:599-604. (Pubitemid 351774360)
19. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-33. PMID: 10910892. (Pubitemid 30616842)
20. Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004;15:S99-106.
21. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74-8. (Pubitemid 38579543)
22. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000;13:381-4.
23. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15:S93-8.
24. Lu M, Suh KR, Lee H-Z, et al. FDA review of ferumoxytol (Feraheme) for the treatment of iron deficiency anemia in adults with chronic kidney disease. Am J Hematology 2010;85:315-19.
25. Coyne DW, Auerbach M. Anemia management in chronic kidney disease: Intravenous iron steps forward. Am J Hematology 2010;85:311-12.
26. Muñoz M, Breymann C, García-Erce JA, et al. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 2008;94:172-83. (Pubitemid 351379653)
27. Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008;19:833-4.
28. Rodgers GM, Becker PS, Bennett CL, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008;6:536-64. (Pubitemid 352007763)
29. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002;32(Suppl 1):70-8. (Pubitemid 41704991)
30. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 1999;55(Suppl):S71-8.
31. García-Erce JA, Cuenca J, Gómez-Ramírez S, et al. Posibilidades de tratamiento de la anemia perioperatoria en cirugía ortopédica y traumatología. Anemia 2009;2:17-27.
32. Edward CQ. Hemochromatosis. In: Greer JP, Foester J, Rodgers GM, et al, eds. Wintrobe's Clinical Hematology. 12th edn. Philadelphia: Wolters Kluwer/Lippincott, Williams & Wilkins, 2009:857-80.
33. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol Mech Dis 2009;4:489-515.
34. Pietrangelo A. Hereditary hemochromatosis: pathogeneis, diagnosis, and treatment. Gastroenterology 2010;139:393-408.
35. Adams PC, Barton JC. Haemochromatosis. Lancet 2007;370:1855-60.
36. Feder J, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8. (Pubitemid 27232800)
37. Vach V, Remacha A, Altès A, et al. Autosomal dominant hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. Blood Cells Mol Dis 2006;36:41-5. (Pubitemid 43061486)
38. Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dtserythropoeitc anemia type I. Blood 2008;112:5241-4.
39. Huang H, Constante M, Layoun A, et al. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood 2009;113:3593-9.
40. Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 2010;50:1144-55.
41. Camaschela C. Diagnosis and treatment of non-HFE haemochromatosis. In: Beaumont C, Beris P, Beuzard Y, et al, eds. Disorder of Iron Homeostasis, Erythrocytes, Erytrhopoiesis. Paris: European School of Haematology, 2006:466-77.
42. García Erce JA, Cortés T, Cremonesi L, et al. [Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza")]. Med Clin (Barc) 2006;127:55-8. (Pubitemid 44086028)
43. Kannengiesser C, Jouanolle AM, Hetet G, et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosilated ferritin in serum and absence of iron overload. Haematologica 2009;94:335-9.
44. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73. (Pubitemid 24265698)
45. Jensen PD, Jensen FT, Christensen T, et al. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003;101:91-6. (Pubitemid 36025892)
46. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003;138:627-33.
47. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001;38(Suppl 1):30-6. (Pubitemid 32110270)
48. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program 2009:215-21.
49. Mavrogeni SI, Markussis V, Kaklamanis L, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 2005;75:241-7. (Pubitemid 41153105)
50. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009;120:1961-8.
51. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010;116:537-43.
52. Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010;116:317-25.
53. Power T, Adams PC. Hemochromatosis patients as voluntary blood donors. Can J Gastroenterol 2004;18:393-6. (Pubitemid 39076993)
54. Rombout-Sestrienkova E, van Noord PA, van Deursen CT, et al. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study. Transfus Apher Sci 2007;36:261-7. (Pubitemid 47089103)
55. Gattermann N, Porter J, Lopes LF, et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin 2005;19(Suppl 1):18-25.
56. Mittelman M, Lugassy G, Merkel D, et al. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr Med Assoc J 2008;10:374-6. (Pubitemid 351902940)
57. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007;31 (Suppl.3):S10-15.
58. Karnon J, Tolley K, Oyee J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008;24:1609-21.
59. Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemia patients: US healthcare system perspective. Pharmacoeconomics 2007;25:329-42. (Pubitemid 46607383)
60. Phatak PD.Brissot P, Bonkovsky H, et al. A Phase I/II, open-label, dose-escalation trial of once-daily oral chelator deferasirox to treat iron overload in HFE-related hereditary hemochromatosis: final results of the core study. Blood (ASH Annual Meeting Abstracts) 2009;114:1514.